Description: Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, upper respiratory, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. It also produces a range of solid oral dosage forms, including tablets and hard gelatin capsules; soft gels; essential oils; ointments; and creams and liquids, as well as prescription drugs. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
Home Page: marksanspharma.com
Grandeur
Mumbai,
400053
India
Phone:
91 22 4001 2000
Officers
| Name | Title |
|---|---|
| Mr. Mark B. Saldanha | Non-Independent Executive Chairman & MD |
| Mr. Jitendra M. Sharma | Chief Financial Officer |
| Mr. Vishal Bhargava | Director Operations |
| Mr. Harshavardhan Panigrahi | Company Secretary, Manager of Legal & Compliance Officer |
| Ms. Sandra Saldanha | Whole-Time Executive Non Independent Director |
| Mr. Varddhman Vikramaditya Jain | Whole-Time Executive Non Independent Director |
| Mr. Sunil K. Rane | Senior Vice President of QC |
| Mr. David Mohammed | Managing Director of Australia Operations |
| Mr. Sathish Kumar | Managing Director of UK Operations |
| Mr. Anjani Kumar | Chief Operating Officer of US Operations |
Exchange: NSE
Country: IN : India
Currency: Indian Rupee (INR)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 40.8144 |
| Price-to-Book MRQ: | 6.7655 |
| Price-to-Sales TTM: | 6.7915 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 1141 |